Acute-phase dynamics and prognostic value of growth differentiation factor-15 in ST-elevation myocardial infarction

• Published in: Clinical chemistry and laboratory medicine Vol. 57; no. 7; pp. 1093 - 1101
• Main Authors: Rueda, Ferran, Lupón, Josep, García-García, Cosme, Cediel, German, Aranda Nevado, M. Cruz, Serra Gregori, Judith, Labata, Carlos, Oliveras, Teresa, Ferrer, Marc, de Diego, Oriol, Serra, Jordi, Revuelta López, Elena, Bayés-Genís, Antoni
• Format: Journal Article
• Language: English
• Published: Germany De Gruyter 01.07.2019; Walter De Gruyter & Company
• Subjects: Acute Disease; Aged; Area Under Curve; biomarkers; Biomarkers - blood; Cardiovascular diseases; Confidence intervals; Differentiation; Electrochemiluminescence; Female; growth differentiation factor 15; Growth Differentiation Factor 15 - blood; Hazards; Health risk assessment; Heart attacks; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mortality; Myocardial infarction; Prognosis; Proportional Hazards Models; Prospective Studies; Radioimmunoassay; Reclassification; Risk Factors; ROC Curve; ST Elevation Myocardial Infarction - mortality; ST Elevation Myocardial Infarction - pathology; ST-elevation myocardial infarction; Statistical models; ST-elevation myocardial infarction; growth differentiation factor 15; prognosis; biomarkers
• ISSN: 1434-6621; 1437-4331; 1437-4331
• DOI: 10.1515/cclm-2018-1189

Background Growth differentiation factor 15 (GDF-15) in ST-elevation myocardial infarction (STEMI) is prognostic in first-generation radioimmunoassays. We examined GDF-15 temporal dynamics in STEMI and its predictive value using a first fully automated GDF-15 electrochemiluminescence assay. Methods In this prospective study, circulating GDF-15 concentration was measured at admission (0 h), 12 h and 24 h in 1026 consecutive STEMI patients treated between February 2011 and May 2016 with primary percutaneous coronary intervention. GDF-15 dynamics (0 h, 12 h, 24 h) and predictive value (30 days and 3 years) were examined. Results Median GDF-15 concentration was 1443 pg/mL at 0 h, 1731 pg/mL at 12 h and 1510 pg/mL at 24 h (p<0.001). During follow-up, 94 patients died (9.2%) and 154 (15.0%) were hospitalized. GDF-15 was a strong predictor of 30-day mortality (hazard ratio [HR] 1.76, 95% confidence interval [CI], 1.33-2.34 at 0 h; HR 2.99 [95% CI, 2.18-4.09] at 12 h, and HR 1.97 [95% CI, 1.47-2.63] at 24 h) in multivariable Cox proportional hazards models. GDF-15 improved discrimination and reclassification of a clinical risk model. GDF-15 was also associated with 3-year mortality (HR 1.31 [95% CI, 1.04-1.65] at 0 h, HR 1.42 [95% CI, 1.10-1.84] at 12 h, and HR 1.51 [95% CI, 1.16-1.96] at 24 h) and 3-year composite of mortality and cardiovascular hospitalization (HR 1.17 [95% CI, 1.01-1.37] at 0 h, HR 1.20 [95% CI, 1.02-1.42] at 12 h, and HR 1.27 [95% CI, 1.08-1.50] at 24 h). Conclusions GDF-15 peaked at 12 h and remained elevated at 24 h in STEMI. GDF-15 measurement during the first 24 h in STEMI is valuable for predicting especially short- but also long-term outcomes, and may be a useful addition to risk stratification.